ArticleHistochemistry and cell biology2025
Bioactive and degradable collagen-based hydrogel encapsulated with microspheres containing basic fibroblast growth factor (bFGF) and interleukin (IL)-10 promotes recovery following traumatic spinal cord injury in rats.
Article in Histochemistry and cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioactive adipose-derived ECM hydrogel loaded with cytokine-releasing microspheres promotes spinal cord repair by suppressing inflammation, apoptosis, oxidative stress, and ferroptosis.Histochemistry and cell biology · 2026Article
- The Scent of a Therapy for Spinal Cord Injury: Growth Factors and Their Potential to Modulate Olfactory Ensheathing Cells.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Traumatic spinal cord injury (TSCI) is a severe event within the central nervous system, leading to the impairment of sensory and motor abilities at the injury site in the spinal cord. Current therapeutic approaches offer limited efficacy in improving recovery, underscoring the need to explore alternative treatments. In the present study, we examined the sustained co-delivery of basic fibroblast growth factor (bFGF) and interleukin-10 (IL-10), encapsulated in microspheres and incorporated into a collagen-based hydrogel, for its effects on the healing of TSCI in an animal model. Seventy-five male Sprague Dawley rats were randomly divided into five groups: control, TSCI, hydrogel, microspheres, and hydrogel loaded with microspheres (Hyd + Micro). Tissue samples were collected from the injury site for further evaluation. Compared to the TSCI group, treatment groups demonstrated notably higher numerical densities of neurons and greater motor neuron health, as well as increased levels of vascular endothelial growth factor (VEGF) and antioxidative factors (catalase [CAT], glutathione [GSH], and superoxide dismutase [SOD]), and improved neurological function scores (electromyography [EMG], Basso-Beattie-Bresnahan (BBB) test, and narrow beam-walking test [NBT]). These changes were most pronounced in the Hyd + Micro group. The treatment also led to a significant decrease in the counts of apoptotic and glial cells, alongside reduced levels of malondialdehyde (MDA) and pro-inflammatory cytokines (IL-1β and TNF-α), with the most notable enhancements seen in the Hyd + Micro group. These findings indicate that the co-delivery of bFGF and IL-10 encapsulated in microspheres within a collagen-based hydrogel provides enhanced neuroprotective effects in TSCI animal models.
Indexed as
Identifiers
40481846What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.